138 related articles for article (PubMed ID: 7747686)
1. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide.
Giustina A; Boni E; Romanelli G; Grassi V; Giustina G
Am J Cardiol; 1995 May; 75(15):1042-7. PubMed ID: 7747686
[TBL] [Abstract][Full Text] [Related]
2. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy.
Manelli F; Desenzani P; Boni E; Bugari G; Negrini F; Romanelli G; Grassi V; Giustina A
Pituitary; 1999 Nov; 2(3):205-10. PubMed ID: 11081155
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular consequences of early-onset growth hormone excess.
Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
[TBL] [Abstract][Full Text] [Related]
6. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.
Colao A; Marzullo P; Cuocolo A; Spinelli L; Pivonello R; Bonaduce D; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2003 Feb; 58(2):169-76. PubMed ID: 12580932
[TBL] [Abstract][Full Text] [Related]
7. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.
Lim MJ; Barkan AL; Buda AJ
Ann Intern Med; 1992 Nov; 117(9):719-26. PubMed ID: 1416573
[TBL] [Abstract][Full Text] [Related]
8. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582
[TBL] [Abstract][Full Text] [Related]
9. Octreotide treatment increases exercise capacity in patients with acromegaly.
Padayatty SJ; Perrins EJ; Belchetz PE
Eur J Endocrinol; 1996 May; 134(5):554-9. PubMed ID: 8664974
[TBL] [Abstract][Full Text] [Related]
10. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics.
Minniti G; Jaffrain-Rea ML; Moroni C; Baldelli R; Ferretti E; Cassone R; Gulino A; Tamburrano G
Clin Endocrinol (Oxf); 1998 Jul; 49(1):101-6. PubMed ID: 9797853
[TBL] [Abstract][Full Text] [Related]
11. Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion.
Rio GD; Velardo A; Mascadri C; Zalteri G; Papi G; Menozzi R; Giustina A
Eur J Endocrinol; 2000 Feb; 142(2):179-86. PubMed ID: 10664528
[TBL] [Abstract][Full Text] [Related]
12. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.
Bogazzi F; Di Bello V; Palagi C; Donne MG; Di Cori A; Gavioli S; Talini E; Cosci C; Sardella C; Brogioni S; Mariani M; Martino E
Clin Endocrinol (Oxf); 2005 May; 62(5):590-6. PubMed ID: 15853830
[TBL] [Abstract][Full Text] [Related]
13. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
14. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.
Fatti LM; Scacchi M; Lavezzi E; Pecori Giraldi F; De Martin M; Toja P; Michailidis G; Stramba-Badiale M; Cavagnini F
Clin Endocrinol (Oxf); 2006 Nov; 65(5):626-30. PubMed ID: 17054464
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.
Merola B; Cittadini A; Colao A; Ferone D; Fazio S; Sabatini D; Biondi B; Saccá L; Lombardi G
J Clin Endocrinol Metab; 1993 Sep; 77(3):790-3. PubMed ID: 8370700
[TBL] [Abstract][Full Text] [Related]
16. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide.
Pereira JL; Rodriguez-Puras MJ; Leal-Cerro A; Martinez A; Garcia-Luna PP; Gavilan I; Pumar A; Astorga R
J Endocrinol Invest; 1991 Jan; 14(1):17-23. PubMed ID: 2045621
[TBL] [Abstract][Full Text] [Related]
17. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Petretta M; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 May; 84(5):1518-23. PubMed ID: 10323372
[TBL] [Abstract][Full Text] [Related]
18. The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study.
Thuesen L; Christensen SE; Weeke J; Orskov H; Henningsen P
Clin Endocrinol (Oxf); 1989 Jun; 30(6):619-25. PubMed ID: 2591060
[TBL] [Abstract][Full Text] [Related]
19. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
Valea A; Carsote M; Ghervan C; Georgescu C
J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
[TBL] [Abstract][Full Text] [Related]
20. Cardiac effect of thyrotoxicosis in acromegaly.
Marzullo P; Cuocolo A; Ferone D; Pivonello R; Salvatore M; Lombardi G; Colao A
J Clin Endocrinol Metab; 2000 Apr; 85(4):1426-32. PubMed ID: 10770177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
